Kerendia Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients With Non-Diabetic Chronic Kidney Disease
March 17, 2026
March 17, 2026
WHIPPANY, New Jersey, March 17 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news:
* * *
KERENDIA(R) (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
* KERENDIA(R) (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerula . . .
* * *
KERENDIA(R) (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
* KERENDIA(R) (finerenone) met its primary endpoint demonstrating a statistically significant improvement vs. placebo in the estimated glomerula . . .